| Patent application number | Description | Published |
|---|
| 20080214489 | Aptamer-mediated intracellular delivery of oligonucleotides - Compositions and methods to mediate the intracellular and sub-cellular delivery of therapeutic, diagnostic and imaging agents, such as oligonucleotides. The compositions of the invention include nucleic acid conjugates comprising a delivery aptamer that is connected to an oligonucleotide. The delivery aptamer may be connected directly to the oligonucleotide, or may be connected indirectly to the oligonucleotide, such as through a linker. The oligonucleotide may be either a therapeutic, diagnostic or imaging oligonucleotide. The methods of the invention are used to increase potency, or alter distribution, half-life, metabolic fate, toxicity and other characteristics. | 09-04-2008 |
| 20090053138 | Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics - Materials and methods are provided for producing and using aptamers as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and/or VEGF receptor or any combination thereof with affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto. | 02-26-2009 |
| 20090075342 | Metabolic profile directed aptamer medicinal chemistry - The present invention provides materials and methods for enhancing aptamers. More specifically, the materials and methods of the present invention are directed toward the modification of aptamers by the identification of one or more cleavage sites, and introduction of a chemical substitution at a position proximal to the cleavage site(s). Such aptamers are useful for the treatment of disease, in diagnostic and detection applications, and/or research, e.g., target validation. | 03-19-2009 |
| 20090081679 | Compositions and methods for in vivo SELEX - The invention describes methods for the in vivo selection of oligonucleotides, preferably aptamers, that persist in biological compartments. In one embodiment, the biological compartment comprises at least one tissue which, in a preferred embodiment, is the blood within the circulatory system of a living mammal. The invention also contemplates oligonucleotides, preferably aptamers, selected through in vivo SELEX that may be linked to therapeutic or diagnostic compositions including other oligonucleotides. | 03-26-2009 |
| 20090105172 | Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics - The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands. | 04-23-2009 |
